FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.
Another FTC report is highly critical of pharmacy benefit managers
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in many prescription drug transa
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
FTC releases second report slamming pharmacy benefit managers
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.
Top three insurers reaped $7.3 billion through their drug middlemen’s markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from ‘excess’ prescription price hikes of 1,000% or more.
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs than it cost them.
FTC says pharmacy benefits managers marked-up generic drug prices for $7.3bn gain
Regulator’s report finds companies ‘hiked costs’ for a range of medicines, including cancer and HIV treatments
FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent
The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on
FTC Release: FTC Releases Second Interim Staff Report on Prescription Drug Middlemen
Report finds PBMs charge significant markups for cancer, HIV, and other critical specialty generic drugs The Federal Trade Commission today published a second interim staff report on the prescription drug middleman industry,
Republican bill seeks to curtail US FTC's merger-busting powers
The U.S. Federal Trade Commission's merger-busting, antitrust enforcement powers are coming under threat as conservatives ...
pharmaphorum32m
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
FTC Prepares to Sue Largest U.S. Apartment Landlord Over Hidden Fees
The FTC is weighing a lawsuit alleging Greystar failed to disclose fees related to trash services and background checks .
FTC set to sue Deere over equipment repair practices, Bloomberg News says
The U.S. Federal Trade Commission has prepared a lawsuit against Deere & Co alleging the company's agricultural equipment ...
Lina Khan Gives Up the Gavel After Contentious 4 Years as FTC Chair
"To my mind, all of this public input and engagement made our work sharper and helped us really set priorities and focus on ...
Will ‘click to cancel’ get canceled? New FTC rule faces legal, political challenges
It takes effect Tuesday but its fate is already in doubt. The new FTC rule faces legal challenges and possible opposition ...
JD Supra20h
FTC Announces 2025 Jurisdictional Threshold Updates for Interlocking Directorates and HSR Filing Thresholds
On January 10, 2025, the Federal Trade Commission (FTC) announced revised jurisdictional thresholds for determining whether a ...
FTC weighs in on Musk's lawsuit against OpenAI
The U.S. Federal Trade Commission weighed in on Friday on Elon Musk's lawsuit seeking to block OpenAI's conversion to a ...